➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Harvard Business School
Medtronic
Moodys
McKinsey

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

CARDIZEM LA Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Cardizem La patents expire, and when can generic versions of Cardizem La launch?

Cardizem La is a drug marketed by Bausch and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has twelve patent family members in eleven countries.

The generic ingredient in CARDIZEM LA is diltiazem hydrochloride. There are twenty-six drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the diltiazem hydrochloride profile page.

Drug patent expirations by year for CARDIZEM LA
Drug Prices for CARDIZEM LA

See drug prices for CARDIZEM LA

Drug Sales Revenue Trends for CARDIZEM LA

See drug sales revenues for CARDIZEM LA

Recent Clinical Trials for CARDIZEM LA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
CAMC Health SystemPhase 4
University of South FloridaN/A
Kowa Research Institute, Inc.Phase 4

See all CARDIZEM LA clinical trials

Pharmacology for CARDIZEM LA
Paragraph IV (Patent) Challenges for CARDIZEM LA
Tradename Dosage Ingredient NDA Submissiondate
CARDIZEM LA TABLET, EXTENDED RELEASE;ORAL diltiazem hydrochloride 021392 2005-08-30
CARDIZEM LA TABLET, EXTENDED RELEASE;ORAL diltiazem hydrochloride 021392 2005-04-25

US Patents and Regulatory Information for CARDIZEM LA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-001 Feb 6, 2003 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Bausch CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-004 Feb 6, 2003 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Bausch CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-002 Feb 6, 2003 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Bausch CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-003 Feb 6, 2003 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Bausch CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-006 Feb 6, 2003 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Bausch CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-005 Feb 6, 2003 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CARDIZEM LA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-002 Feb 6, 2003   Start Trial   Start Trial
Bausch CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-005 Feb 6, 2003   Start Trial   Start Trial
Bausch CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-001 Feb 6, 2003   Start Trial   Start Trial
Bausch CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-005 Feb 6, 2003   Start Trial   Start Trial
Bausch CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-003 Feb 6, 2003   Start Trial   Start Trial
Bausch CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-004 Feb 6, 2003   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Baxter
Merck
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.